0000000000818951

AUTHOR

A. Spadaro

showing 4 related works from this author

Randomised trial of two different daily doses of interferon-α versus classical therapy in treatment-naïve patients with chronic hepatitis C

2002

Objective: To evaluate the efficacy and tolerability of two different daily doses of interferon-α (lymphoblastoid-IFNα-N1, Wellferon®) [IFNα] for 2 months, followed by the same dose on alternate days for up to 1 year, versus administration on alternate days for 1 year. Patients and methods: A non-blind, randomised study of outpatients with chronic hepatitis C at five centres in Sicily, Italy. Ninety-seven consecutive treatment-naïve patients [72 patients with hepatitis C virus (HCV) genotype 1b infection] with histological chronic hepatitis C were included in the study and randomised to receive IFNα subcutaneously: 5 million international units (MIU) daily for 2 months, followed by the same…

PharmacologyPharmacology (medical)
researchProduct

Randomised Trial of Two Different Daily Doses of Interferon-α versus Classical Therapy in Treatment-Naïve Patients with Chronic Hepatitis C.

2018

To evaluate the efficacy and tolerability of two different daily doses of interferon-α (lymphoblastoid-IFNα-N1, Wellferon®) [IFNα] for 2 months, followed by the same dose on alternate days for up to 1 year, versus administration on alternate days for 1 year. A non-blind, randomised study of outpatients with chronic hepatitis C at five centres in Sicily, Italy. Ninety-seven consecutive treatment-naive patients [72 patients with hepatitis C virus (HCV) genotype 1b infection] with histological chronic hepatitis C were included in the study and randomised to receive IFNα subcutaneously: 5 million international units (MIU) daily for 2 months, followed by the same dose on alternate days for up to…

medicine.medical_specialtyDosebusiness.industryHepatitis C virusGeneral Medicinemedicine.disease_causeGastroenterologyGroup AGroup BSurgeryDiscontinuationPharmacotherapyTolerabilityInternal medicineMedicinePharmacology (medical)businessAdverse effectClinical drug investigation
researchProduct

Safety and efficacy of peginterferon alpha 2a plus mycofenolatemofetile and peginterferon alpha 2a plus Ribavirin in unresponsive patients with chron…

2005

researchProduct

Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study

2019

Background: Results from retrospective studies suggest that use of neuromuscular blocking agents during general anaesthesia might be linked to postoperative pulmonary complications. We therefore aimed to assess whether the use of neuromuscular blocking agents is associated with postoperative pulmonary complications. Methods: We did a multicentre, prospective observational cohort study. Patients were recruited from 211 hospitals in 28 European countries. We included patients (aged ≥18 years) who received general anaesthesia for any in-hospital procedure except cardiac surgery. Patient characteristics, surgical and anaesthetic details, and chart review at discharge were prospectively collecte…

Pulmonary and Respiratory Medicinepulmonary complications muscle relaxants Post-anaesthesia complicationsNeuromuscular Blockadepulmonary complication muscle relaxantneuromuscular block ; postoperative pulmonary complicationbusiness.industryRetrospective cohort studypost-operative pulmonary complicationsNeuromuscular monitoringNeuromuscular Blocking AgentsSugammadexNOAnaesthesia03 medical and health sciences0302 clinical medicine030228 respiratory systemAnesthesiaMedicineGeneral anaesthesiaNeuromuscular Agents030212 general & internal medicineMED/41 - ANESTESIOLOGIAProspective cohort studybusinessmedicine.drug
researchProduct